Skip to main content

Articles

Page 29 of 34

  1. Two methods of non-invasive brain stimulation, transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), have demonstrable positive effects on cognition and can ameliorate neu...

    Authors: Greg J Elder and John-Paul Taylor
    Citation: Alzheimer's Research & Therapy 2014 6:74
  2. Recently, a whole-exome sequencing (WES) study showed that a rare variant rs145999145 composed of p.Val232Met located in exon 7 of the phospholipase D3 (PLD3) gene confers a doubled risk for late-onset Alzheimer’...

    Authors: Jun-ichi Satoh, Yoshihiro Kino, Yoji Yamamoto, Natsuki Kawana, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima
    Citation: Alzheimer's Research & Therapy 2014 6:70
  3. α-Synuclein is an abundantly expressed neuronal protein that is at the center of focus in understanding a group of neurodegenerative disorders called α-synucleinopathies, which are characterized by the presenc...

    Authors: Woojin Scott Kim, Katarina Kågedal and Glenda M Halliday
    Citation: Alzheimer's Research & Therapy 2014 6:73
  4. Therapeutic education is expanding in the management of Alzheimer’s disease (AD) patients. Several studies have revealed a positive impact of therapeutic educational programmes on the caregiver’s burden and/or...

    Authors: Hélène Villars, Virginie Gardette, Amélie Perrin, Christophe Hein, Sophie Elmalem, Eva de Peretti, Audrey Zueras, Bruno Vellas and Fati Nourhashémi
    Citation: Alzheimer's Research & Therapy 2014 6:66
  5. The identification of early, preferably presymptomatic, biomarkers and true etiologic factors for Alzheimer’s disease (AD) is the first step toward establishing effective primary and secondary prevention progr...

    Authors: Oscar Sotolongo-Grau, Pedro Pesini, Sergi Valero, Asunción Lafuente, Mar Buendía, Virginia Pérez-Grijalba, Itziar San Josè, Marta Ibarria, Miguel A Tejero, Joan Giménez, Isabel Hernández, Lluís Tárraga, Agustín Ruiz, Mercè Boada and Manuel Sarasa
    Citation: Alzheimer's Research & Therapy 2014 6:56
  6. Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, si...

    Authors: Sebastian Schade and Brit Mollenhauer
    Citation: Alzheimer's Research & Therapy 2014 6:72
  7. Diagnostic effectiveness of Ioflupane I 123 injection (DaTSCANTM, DaTscanTM, or [123I]FP-CIT or ioflupane [123I]) SPECT imaging, was assessed in patients with clinically uncertain parkinsonian syndrome (CUPS).

    Authors: Nin Bajaj, Robert A Hauser, John Seibyl, Andreas Kupsch, Michail Plotkin, Chris Chen and Igor D Grachev
    Citation: Alzheimer's Research & Therapy 2014 6:67
  8. Compared to Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) is usually associated with a more complex clinical picture and higher burden of care. Yet, few investigations have been performed on comorb...

    Authors: Seyed-Mohammad Fereshtehnejad, Soheil Damangir, Pavla Cermakova, Dag Aarsland, Maria Eriksdotter and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2014 6:65
  9. The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes exp...

    Authors: Philip H Montenigro, Christine M Baugh, Daniel H Daneshvar, Jesse Mez, Andrew E Budson, Rhoda Au, Douglas I Katz, Robert C Cantu and Robert A Stern
    Citation: Alzheimer's Research & Therapy 2014 6:68
  10. Many age-related health problems have been associated with dementia, leading to the hypothesis that late-life dementia may be determined less by specific risk factors, and more by the operation of multiple hea...

    Authors: Xiaowei Song, Arnold Mitnitski and Kenneth Rockwood
    Citation: Alzheimer's Research & Therapy 2014 6:54
  11. The aim of this review was to investigate whether there is a faster cognitive decline in dementia with Lewy bodies (DLB) than in Alzheimer’s disease (AD) over time.

    Authors: Monica H Breitve, Luiza J Chwiszczuk, Minna J Hynninen, Arvid Rongve, Kolbjørn Brønnick, Carmen Janvin and Dag Aarsland
    Citation: Alzheimer's Research & Therapy 2014 6:53
  12. The association of military blast exposure and brain injury was first appreciated in World War I as commotio cerebri, and later as shell shock. Similar injuries sustained in modern military conflicts are now c...

    Authors: Lee E Goldstein, Ann C McKee and Patric K Stanton
    Citation: Alzheimer's Research & Therapy 2014 6:64
  13. Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...

    Authors: Victor L Villemagne, Seong Yoon Kim, Christopher C Rowe and Takeshi Iwatsubo
    Citation: Alzheimer's Research & Therapy 2014 6:62
  14. The biological basis of cognitive impairment in parkinsonian diseases is believed to be multifactorial. We investigated the contribution of dopamine deficiency to cognition in Parkinson disease (PD) and dement...

    Authors: Marta Marquie, Joseph J Locascio, Dorene M Rentz, J Alex Becker, Trey Hedden, Keith A Johnson, John H Growdon and Stephen N Gomperts
    Citation: Alzheimer's Research & Therapy 2014 6:52
  15. Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer’s disease (AD), little is known about the long term effects of cholinergic treatment on global c...

    Authors: Pearl Behl, Jodi D Edwards, Alexander Kiss, Krista L Lanctot, David L Streiner, Sandra E Black and Donald T Stuss
    Citation: Alzheimer's Research & Therapy 2014 6:48
  16. Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer’s disease (AD) and normal elderly controls. Although the presence o...

    Authors: Joel Ramirez, Alicia A McNeely, Christopher JM Scott, Donald T Stuss and Sandra E Black
    Citation: Alzheimer's Research & Therapy 2014 6:49
  17. Pathologically modified tau protein is the main feature of Alzheimer’s disease (AD) and related tauopathies. Therefore, immunotherapies that target mis-disordered tau represent a promising avenue for the disea...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:45
  18. We have identified structural determinants on tau protein that are essential for pathological tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8, r...

    Authors: Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak and Michal Novak
    Citation: Alzheimer's Research & Therapy 2014 6:44
  19. This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer’s disease. These considerations were generat...

    Authors: Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, Derek Hill, Andrew Lockhart, Mark E Schmidt, Martin R Turner, Stefania Mondello and William Z Potter
    Citation: Alzheimer's Research & Therapy 2014 6:51
  20. The aim of this investigation was to assess the effect of galantamine, an acetylcholinesterase inhibitor and allosteric modulator of nicotinic receptors, on brain atrophy in individuals with mild cognitive imp...

    Authors: Niels D Prins, Wiesje A van der Flier, Dirk L Knol, Nick C Fox, H Robert Brashear, Jeffrey S Nye, Frederik Barkhof and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2014 6:47
  21. Alzheimer’s disease (AD) is the major cause of dementia among the elderly. Finding blood-based biomarkers for disease diagnosis and prognosis is urgently needed.

    Authors: Oscar Alzate, Cristina Osorio, Robert M DeKroon, Ana Corcimaru and Harsha P Gunawardena
    Citation: Alzheimer's Research & Therapy 2014 6:43
  22. Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer’s disease brain are orders of magnitude greater than soluble amyloid-beta oligomer levels. Monomeric amyloid-beta has no known direct ...

    Authors: William F Goure, Grant A Krafft, Jasna Jerecic and Franz Hefti
    Citation: Alzheimer's Research & Therapy 2014 6:42
  23. Although Alzheimer’s disease (AD) is associated with early death, its life expectancy differs greatly between patients. A better understanding of this heterogeneity may reveal important disease mechanisms unde...

    Authors: Katarina Nägga, Carina Wattmo, Yi Zhang, Lars-Olof Wahlund and Sebastian Palmqvist
    Citation: Alzheimer's Research & Therapy 2014 6:41
  24. This report summarizes the findings presented at the Alzheimer’s Research UK Conference, which was held in Oxford on 25 and 26 March 2014 and which provided an overview of current dementia research from fundam...

    Authors: Rosa M Sancho, Simon H Ridley, Laura E Phipps and Eric Karran
    Citation: Alzheimer's Research & Therapy 2014 6:40
  25. MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer’s disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has...

    Authors: Mariet Allen, Michaela Kachadoorian, Zachary Quicksall, Fanggeng Zou, High Seng Chai, Curtis Younkin, Julia E Crook, V Shane Pankratz, Minerva M Carrasquillo, Siddharth Krishnan, Thuy Nguyen, Li Ma, Kimberly Malphrus, Sarah Lincoln, Gina Bisceglio, Christopher P Kolbert…
    Citation: Alzheimer's Research & Therapy 2014 6:39
  26. The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer’s disease (AD) and related disorders is clearly established. However, the question remains on how to use these data, whi...

    Authors: Sylvain Lehmann, Julien Dumurgier, Susanna Schraen, David Wallon, Frédéric Blanc, Eloi Magnin, Stéphanie Bombois, Olivier Bousiges, Dominique Campion, Benjamin Cretin, Constance Delaby, Didier Hannequin, Barbara Jung, Jacques Hugon, Jean-Louis Laplanche, Carole Miguet-Alfonsi…
    Citation: Alzheimer's Research & Therapy 2014 6:38
  27. Alzheimer’s disease (AD) is characterized by the deposition of tau and amyloid in the brain. Although the core cerebrospinal fluid (CSF) AD biomarkers amyloid β peptide 1–42 (Aβ1–42), total tau (t-tau) and phosph...

    Authors: Jon B Toledo, Ané Korff, Leslie M Shaw, John Q Trojanowski and Jing Zhang
    Citation: Alzheimer's Research & Therapy 2014 6:36
  28. Alzheimer’s disease (AD) is characterized by the formation of senile plaques and neurofibrillary tangles composed of phosphorylated Tau. Several findings suggest that correcting signal dysregulation for Tau ph...

    Authors: Yasuko Kitagishi, Atsuko Nakanishi, Yasunori Ogura and Satoru Matsuda
    Citation: Alzheimer's Research & Therapy 2014 6:35
  29. Administration of several cardiovascular drugs has an effect on dementia. We aimed to investigate whether there are differences in the use of cardiovascular medication between different dementia disorders.

    Authors: Pavla Cermakova, Seyed-Mohammad Fereshtehnejad, Kristina Johnell, Bengt Winblad, Maria Eriksdotter and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2014 6:34

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2014 6:63

  30. Vascular dementia is the second most common cause of dementia after Alzheimer’s disease (AD). In addition, it is estimated that almost half of all AD patients have significant cerebrovascular disease comorbid ...

    Authors: Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun and Donna M Wilcock
    Citation: Alzheimer's Research & Therapy 2014 6:32
  31. Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer’s disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the prefer...

    Authors: Hadar Feinberg, José W Saldanha, Linnea Diep, Amita Goel, Angela Widom, Geertruida M Veldman, William I Weis, Dale Schenk and Guriqbal S Basi
    Citation: Alzheimer's Research & Therapy 2014 6:31
  32. The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted to identifying and validating pathways through which therapeutics may alleviate tau burde...

    Authors: Casey Cook, Jeannette N Stankowski, Yari Carlomagno, Caroline Stetler and Leonard Petrucelli
    Citation: Alzheimer's Research & Therapy 2014 6:29
  33. Alzheimer’s disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble ag...

    Authors: Markus P Kummer and Michael T Heneka
    Citation: Alzheimer's Research & Therapy 2014 6:28
  34. Lower angiotensin-converting enzyme (ACE) activity could increase the risk of Alzheimer’s disease (AD) as ACE functions to degrade amyloid-β (Aβ). Therefore, we investigated whether ACE protein and activity le...

    Authors: Hadassa M Jochemsen, Charlotte E Teunissen, Emma L Ashby, Wiesje M van der Flier, Ruth E Jones, Mirjam I Geerlings, Philip Scheltens, Patrick G Kehoe and Majon Muller
    Citation: Alzheimer's Research & Therapy 2014 6:27
  35. Vaccination against amyloid-β protein (Aβ42) induces high levels of antibody, making it a promising strategy for treating Alzheimer’s disease (AD). One drawback in the past was that clinical trial approval was...

    Authors: Shuang Wang, Yang Yu, Shuang Geng, Dongmei Wang, Li Zhang, Xiaoping Xie, Bing Wu, Chaofan Li, Hanqian Xu, Xiaolin Li, Yanxin Hu, Lianfeng Zhang, Christoph Kaether and Bin Wang
    Citation: Alzheimer's Research & Therapy 2014 6:26
  36. The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF) of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB)...

    Authors: Oskar Hansson, Sara Hall, Annika Öhrfelt, Henrik Zetterberg, Kaj Blennow, Lennart Minthon, Katarina Nägga, Elisabet Londos, Shiji Varghese, Nour K Majbour, Abdulmonem Al-Hayani and Omar MA El-Agnaf
    Citation: Alzheimer's Research & Therapy 2014 6:25
  37. The Alzheimer’s Drug Discovery Foundation’s 14th International Conference on Alzheimer’s Drug Discovery was held on 9 and 10 September in Jersey City, NJ, USA. This annual meeting highlights novel therapeutic ...

    Authors: Lauren G Friedman, Katherine Price, Rachel F Lane, Aaron J Carman, Penny A Dacks, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2014 6:22
  38. Lewy body dementia (LBD) is the second most common neurodegenerative dementia in older adults, yet there remains a delay in diagnosis that limits healthcare providers’ ability to maximize therapeutic outcomes ...

    Authors: Yael R Zweig and James E Galvin
    Citation: Alzheimer's Research & Therapy 2014 6:21
  39. Emerging evidence suggests that decreased adult hippocampal neurogenesis represents an early critical event in the course of Alzheimer’s disease (AD). In mice, adult neurogenesis is reduced by knock-in alleles...

    Authors: Keith A Wesnes, Peter Annas, Hans Basun, Chris Edgar and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2014 6:20